Parkinson’s disease (PD) is the second most common neurodegenerative disease (de Lau and Breteler, 2006) that is well known for its progression, which involves increased disability and burden (Bloem et al., 2021). Worsening is noted not only in motor symptoms but also in nonmotor ones, particularly cognition. The rate of disease progression varies among people with PD (PwP). In the ongoing Parkinson’s Progression Markers Initiative cohort study, approximately one-third of untreated PwP exhibited rapid progression during the first 2 years of follow-up. By contrast, the remaining PwP had a slow progressive course (Chen-Plotkin et al., 2018). Unfortunately, no disease-modifying therapy for halting disease progression and no predictor for assessing disease progression are available.

Synapses are sites of neuronal communication, and synaptic degeneration is an early functional pathogenic event in neurodegenerative diseases such as Alzheimer’s disease (AD) and PD (Picconi et al., 2012; Arendt, 2009). Postmortem studies have revealed a substantial loss of dopamine terminals in the putamen and amygdala (Iseki et al., 2001; Kordower et al., 2013). In addition, the loss of glutamatergic corticostriatal synapses has been reported (Stephens et al., 2005). Mitochondrial dysfunction contributes to some of the synaptic loss in PD, and the buildup of α-synuclein, a key synaptic protein, plays a significant role in the development of PD (Gcwensa et al., 2021). Assessment of synaptic proteins in the cerebrospinal fluid (CSF) can reflect synaptic loss in patients with neurological diseases and is a key area of research interest. Significant research has been directed toward evaluating synaptic changes in CSF to enhance early diagnosis of neurodegenerative diseases before neuron loss and track disease progression (Lleó et al., 2019; Milà-Alomà et al., 2021; Bereczki et al., 2017). Several synaptic proteins are promising biomarkers of synaptic function. Synaptosome-associated protein 25 (SNAP-25) is a presynaptic protein that plays a crucial role in neuronal survival, vesicular exocytosis, and neurite outgrowth (Antonucci et al., 2016). Increased CSF levels of SNAP-25 have been reported in PwP (Bereczki et al., 2017). In addition, growth-associated protein 43 (GAP-43) is a presynaptic protein anchored to the cytoplasmic side of the presynaptic plasma membrane (Benowitz and Routtenberg, 1997). CSF levels of GAP-43 have been reported to be significantly higher in patients with AD than in healthy controls (HCs) (Sjögren et al., 2001). Synaptotagmin-1 is a calcium sensor vesicle protein that is vital for rapid synchronous neurotransmitter release in hippocampal neurons (Courtney et al., 2019). Significantly increased CSF levels of synaptotagmin-1 have been reported in patients with AD and mild cognitive impairment (Öhrfelt et al., 2019). Regarding PD, one study reported an increase in the level of CSF SNAP-25 but not Ras-related protein 3A or neurogranin. Moreover, treated PwP exhibited higher CSF levels of SNAP-25 than did their drug-naïve counterparts (Bereczki et al., 2017).

However, collecting CSF is somewhat invasive and necessary for clinical assessments, but it may cause side effects like headaches after the procedure. Although studies have assessed blood biomarkers for PD diagnosis and progression, the results are conflicting. A lack of correlation between the peripheral blood content and the brain because of the blood–brain barrier (BBB) is a major obstacle to the identification of blood biomarkers for neurodegenerative diseases (Qin et al., 2016). Assessment of peripheral blood extracellular vesicle (EV) proteins can be an alternative approach. EVs are tiny vesicles covered with a lipid membrane. They contain proteins, lipids, and nucleic acid responsible for cell-to-cell signal transmission. The integrity of EVs can be maintained when crossing the BBB (Jan et al., 2017). Plasma EV biomarkers are being rapidly developed for PD (Leggio et al., 2021). EV-cargo α-synuclein has been the most studied target that has exhibited strong potential for distinguishing PwP from HCs and other patients with atypical parkinsonism (Chung et al., 2021b; Niu et al., 2020; Zheng et al., 2021; Si et al., 2019; Stuendl et al., 2021). EV-cargo tau, β-amyloid, neurofilament light chain, brain-derived neurotrophic factor, and insulin receptor substrate have also been assessed in PwP (Athauda et al., 2019; Chou et al., 2020; Chung et al., 2020d; Chung et al., 2020a; Chung et al., 2021a). These results indicate the potential role of EV content as biomarkers in PD.

The levels of synaptic proteins in blood exosomes, a specific type of EV, decrease in patients with AD and frontotemporal dementia (Goetzl et al., 2016). Moreover, blood exosomal SNAP-25, GAP-43, neurogranin, and synaptotagmin-1 levels are lower in patients with AD. A combination of exosomal synaptic protein biomarkers could predict cognitive impairment (Jia et al., 2021). A cross-sectional study showed that PwP have lower levels of synaptic proteins in neuron-derived exosomes in their blood compared to healthy individuals, allowing for an approximately 80% accurate distinction between PwP and HCs (Agliardi et al., 2021). Considering the plasma EVs remain stable up to 90 d (Kalra et al., 2013), this prevents the fluctuation of free-form synaptic proteins because of transient surge or degradation. Moreover, SNAP-25 is transported in the blood by EVs (Agliardi et al., 2019). However, there is no information from the cohort study of PD. Therefore, the association between plasma EV synaptic proteins and PD progression was assessed and determined whether plasma EV synaptic proteins could be used as clinical biomarkers to predict the progression of PD.

The participants’ demographic data at baseline and 1-year follow-up are presented in Table 1. In total, 144 participants (101 PwP and 43 HCs, all of them are Taiwanese) were followed up. No significant difference was noted in plasma EV SNAP-25, GAP-43, and synaptotagmin-1 levels at baseline and follow-up between PwP and HCs after adjustment for age and sex (Figure 1A [representative image] and Figure 1B–D [dot plot]).

Figure 1

Download asset Open asset

Figure 1—source data 1

The original blot image of the representative GAP-43 (A), synaptotagmin-1 (B), SNAP-25 (C), and HSP-70 (D).

https://cdn.elifesciences.org/articles/87501/elife-87501-fig1-data1-v1.pdf

Download elife-87501-fig1-data1-v1.pdf

The association between changes in plasma EV synaptic protein levels and clinical parameters in PwP was assessed through a generalized linear model (Table 2). The changes in the total score of Unified Parkinson’s Disease Rating Scale (UPDRS)-II was positively associated with the change in plasma EV synaptic proteins (SNAP-25, GAP-43, and synaptotagmin-1). The changes in total score of UPDRS-III and akinetic rigidity (AR) subscore were significantly associated with the changes in plasma EV GAP-43 and synaptotagmin-1. The changes in Mini-Mental Status Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores were nonsignificantly associated with the changes in plasma EV synaptic protein levels.

The association between the severity of clinical parameters of PD at follow-up and baseline plasma EV synaptic protein levels was further evaluated. After adjustment for age, sex, and disease duration, the plasma EV SNAP-25, GAP-43, and synaptotagmin-1 levels were nonsignificantly associated with the UPDRS-II, UPDRS-III, MMSE, and MoCA scores at follow-up (Figure 2; for details, refer to Supplementary file 1). However, when UPDRS-III scores were divided into tremor, AR, and postural instability and gait disturbance (PIGD) subscores, the initial levels of plasma EV SNAP-25 and GAP-43 showed a significant positive correlation with PIGD subscores at follow-up. Additionally, a similar trend was observed with the plasma EV synaptotagmin-1 level.

Figure 2

Download asset Open asset

Participants with PD were grouped based on their baseline plasma EV synaptic protein levels using the first quartile as a cutoff. Overall, PwP with elevated baseline levels of plasma EV synaptic proteins had poor total scores of UPDRS-II and UPDRS-III and poor PIGD subscores of UPDRS-III (Table 3). In contrast, a significant greater improvement in the tremor score was noted in the PwP with elevated baseline levels of plasma EV synaptic proteins. Moreover, PwP with elevated baseline levels of plasma EV synaptic proteins exhibited significantly greater deterioration, as assessed using the UPDRS-II scores and PIGD subscores in UPDRS-III. After adjusting for age, sex, and disease duration, repeated-measures analysis of covariance showed that PwP who had elevated levels of any one plasma EV synaptic protein had significantly higher UPDRS-II scores and PIGD subscores at follow-up, but not at baseline, compared to those without elevated levels. This indicates a notably faster deterioration in the patient group with elevated plasma EV synaptic protein levels (Figure 3).

Figure 3

Download asset Open asset

Although no significant difference in plasma EV synaptic protein levels was observed between PwP and HCs in the research, alterations in plasma EV synaptic protein levels in PwP were linked to motor decline. In addition, baseline plasma EV synaptic protein levels were associated with clinical outcomes, as assessed using PIGD subscores at follow-up. PwP with elevated baseline levels of any one plasma EV synaptic protein (SNAP-25, GAP-43, or synaptotagmin-1) exhibited significant deterioration in the activities of daily living (as assessed by UPDRS-II scores and PIGD subscores in UPDRS-III) between baseline and follow-up. The promising potential of plasma EV synaptic proteins as biomarkers for PD, particularly its progression, was indicated.

Significant worsening of UPDRS-II scores and PIGD subscores in UPDRS-III was noted in PwP with higher baseline levels of plasma EV synaptic proteins (first quartile). UPDRS-II is a crucial but underestimated parameter for assessing PwP; it can be used to assess the daily functional capability related to motor symptoms in PwP without temporary drug interruptions, as in the case of UPDRS-III (Rodriguez-Blazquez et al., 2013; Sampaio, 2009). PIGD subtype is linked to a higher Lewy bodies burden, a rapid decline, and greater risks of cognitive impairment, falls, and mortality compared to the tremor-dominant (TD) subtype. The TD subtype, in contrast, tends to have a relatively benign course (Johnson et al., 2016; Burn et al., 2006; Ren et al., 2020; Nutt, 2016). PwP may convert from the TD subtype to the PIGD subtype during disease progression (Lee et al., 2019). Moreover, PIGD-related motor symptoms respond to dopaminergic medications to a lesser extent than do tremor-, akinesia-, and rigidity-related symptoms (Kempster et al., 2007), which may more directly reflect the progression of the disease. PwP with elevated levels of any one plasma EV synaptic protein exhibited greater deterioration, as assessed using UPDRS-II scores and PIGD subscores, as observed in the research. High EV synaptic protein levels conventionally indicate increased synaptogenesis; this contrasts the synaptic loss pattern noted in PD. Decreased blood exosomal synaptic protein levels have been reported in patients with AD and frontotemporal dementia (Goetzl et al., 2016). However, in PwP who are at the early disease stage, compensatory synaptic sprouting and increased synaptic plasticity are noted in the striatum. This compensation, also known as motor reserve, may temporarily decrease the clinical disease burden. However, the patient would be more vulnerable to deterioration if the compensation is overshadowed by degeneration (Chung et al., 2020e). For instance, in one study, PwP who engaged in higher premorbid exercises exhibited milder motor symptoms despite having a similar gradient of striatal dopaminergic reduction at baseline; however, they exhibited more rapid deterioration (Sunwoo et al., 2017). The inclusion of primarily early-stage PwP (mean disease duration of less than 3 y) with mild disease burden (baseline UPDRS-II score = 8.49) in the research suggests that elevated plasma EV synaptic protein levels might indicate activation of a compensatory process. Such PwP are at an increased risk of rapid deterioration and disease progression and should be candidates for disease-modifying interventions, including pharmacological and nonpharmacological treatments.

A notable pioneering role is the evaluation of changes in plasma EV synaptic protein levels and elucidating the relationship between these changes and cognitive decline in PwP. Considering the well-established role of synaptic degeneration and plasticity in PD, the theoretical background of the use of these synaptic proteins as plasma EV biomarkers for PD is confirmed. Moreover, most synaptic proteins are neuron derived, thereby preventing contamination from non-neuronal tissues. The significant link between changes in plasma EV synaptic protein levels and changes in UPDRS-II, UPDRS-III, and AR subscore indicates the effectiveness of these proteins in detecting motor decline in PwP. This suggests that these proteins could serve as an objective parameter for future disease-modification clinical trials. Elevated baseline plasma EV synaptic protein levels can also predict rapid deterioration in PwP, highlighting the importance of motor reserve and synaptic plasticity in the progression of PD for future research. Although no single synaptic protein can precisely predict the progression of PD, these protein targets may be considered for inclusion in a biomarker panel. They can be analyzed using an artificial intelligence-assisted artificial neural network, a method commonly used to predict outcomes in various neurological diseases (Chung et al., 2020b; Chung et al., 2020c; James et al., 2021; Chou et al., 2022).

There were several limitations to the study. Technically, semiquantitative assessment of plasma EV synaptic protein (SNAP-25, GAP-43, and synaptotagmin-1) levels was performed using western blot analysis. The lack of absolute values, that is, from the results of enzyme-linked immunosorbent assay, limits further clinical application. In addition, because numerous synaptic proteins are involved in the pathogenesis of PD, the three selected proteins may not reflect all features of the synaptic condition. The selection of HSP-70 as the control for the synaptic proteins quantification of plasma EV is not undisputable. Two types of EV proteins are used for this role: membrane proteins and intravesicular proteins. Membrane proteins include CD9, CD63, and CD81; intravesicular proteins include TSG101, annexins, and chaperone proteins, such as HSP-70. Since the expression of HSP-70 is usually steady, the HSP-70 was used as the internal control, but it is a limitation of the present study. Furthermore, the evaluation of the overall plasma EVs rather than specifically focusing on neuron-derived exosomes potentially introduced a bias toward somatic-origin EVs. Nonetheless, it is worth noting that synaptic proteins primarily originate from neurons. Even when considering neuron-derived exosomes, it is important to recognize that they are not exclusively derived from the brain, which can lead to contamination from the peripheral nervous system. The final technical issue in the present study was the relatively small size of the isolated EVs. Despite the primary focus on isolating exosomes, which are the smallest type of EVs, it is important to consider that the presence of small-sized EVs could potentially be attributed to EV fragmentation that occurs during the freezing and thawing processes. Regarding the limitation from the cohort, it is also worth mentioning that the 1-year follow-up period to assess the progression of PD was relatively short and may have been insufficient to detect significant disease progression. On the other hand, the evaluation of motor symptoms took place in a hospital setting. In this context, patients were not asked to stop taking their anti-PD medications. This decision was made due to safety concerns, such as the risk of falls. As a result, specific motor symptoms, particularly tremor and AR, which are more sensitive to medication compared to PIGD, may have been effectively managed by the anti-PD medications. This could potentially explain the improvement in tremor observed between the baseline and 1-year follow-up, especially among PwP with elevated baseline plasma EV synaptic proteins. Additionally, synaptic dysfunction is a frequently observed phenomenon in several neurological diseases, and it is not exclusive to PD. Consequently, the HC group may have included individuals with coexisting neurological conditions in the research, potentially explaining the lack of a significant difference between the PD group and the HCs. However, this approach also illuminates the significance of synaptic dysfunction in the advancement of PD. This insight can be invaluable for monitoring disease progression, particularly in the context of clinical trials focused on disease modification. Choosing the first quartile as a cutoff value of plasma EV synaptic proteins is also one of the limitations of the study. While developing new biomarkers, there was no clear cutoff value as reference for the continuous variable, and percentile is considered for predicting the prognosis (Duarte, 2021). Further studies are required to validate this application. Lastly, the results form a mono-centric, small-scale and short-period PD cohort required further validation.

In conclusion, the changes in the levels of plasma EV synaptic proteins, namely SNAP-25, GAP-43, and synaptotagmin-1, are associated with motor decline in PwP. Elevated baseline plasma EV synaptic protein levels can predict increased deterioration of motor function, particularly PIGD symptoms, in PwP. Plasma EV synaptic proteins have the potential to be used as biomarkers of PD progression and detection. A longer longitudinal follow-up is warranted to clearly assess the prognostic efficacy of plasma EV synaptic proteins in PwP.

The dataset is deposited in Dryad: https://doi.org/10.5061/dryad.4qrfj6qh9.

1. 1. Hong CT
   2. Chung CC
   3. Yu RC
   4. Chan L

   (2024) Dryad Digital Repository

   Plasma extracellular vesicle synaptic proteins as biomarkers of clinical progression in patients with Parkinson's disease.

   https://doi.org/10.5061/dryad.4qrfj6qh9

1. 1. Agliardi C
   2. Guerini FR
   3. Zanzottera M
   4. Bianchi A
   5. Nemni R
   6. Clerici M

   (2019) SNAP-25 in serum is carried by exosomes of neuronal origin and is a potential biomarker of Alzheimer’s Disease

   Molecular Neurobiology 56:5792–5798.

   https://doi.org/10.1007/s12035-019-1501-x

   • PubMed
   • Google Scholar
2. 1. Agliardi C
   2. Meloni M
   3. Guerini FR
   4. Zanzottera M
   5. Bolognesi E
   6. Baglio F
   7. Clerici M

   (2021) Oligomeric α-Syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson’s disease

   Neurobiology of Disease 148:105185.

   https://doi.org/10.1016/j.nbd.2020.105185

   • PubMed
   • Google Scholar
3. 1. Antonucci F
   2. Corradini I
   3. Fossati G
   4. Tomasoni R
   5. Menna E
   6. Matteoli M

   (2016) SNAP-25, a known presynaptic protein with emerging postsynaptic functions

   Frontiers in Synaptic Neuroscience 8:7.

   https://doi.org/10.3389/fnsyn.2016.00007

   • PubMed
   • Google Scholar
4. 1. Arendt T

   (2009) Synaptic degeneration in Alzheimer’s disease

   Acta Neuropathologica 118:167–179.

   https://doi.org/10.1007/s00401-009-0536-x

   • PubMed
   • Google Scholar
5. 1. Athauda D
   2. Gulyani S
   3. Karnati HK
   4. Li Y
   5. Tweedie D
   6. Mustapic M
   7. Chawla S
   8. Chowdhury K
   9. Skene SS
   10. Greig NH
   11. Kapogiannis D
   12. Foltynie T

   (2019) Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial

   JAMA Neurology 76:420–429.

   https://doi.org/10.1001/jamaneurol.2018.4304

   • PubMed
   • Google Scholar
6. 1. Benowitz LI
   2. Routtenberg A

   (1997) GAP-43: an intrinsic determinant of neuronal development and plasticity

   Trends in Neurosciences 20:84–91.

   https://doi.org/10.1016/s0166-2236(96)10072-2

   • PubMed
   • Google Scholar
7. 1. Bereczki E
   2. Bogstedt A
   3. Höglund K
   4. Tsitsi P
   5. Brodin L
   6. Ballard C
   7. Svenningsson P
   8. Aarsland D

   (2017) Synaptic proteins in CSF relate to Parkinson’s disease stage markers

   NPJ Parkinson’s Disease 3:7.

   https://doi.org/10.1038/s41531-017-0008-2

   • PubMed
   • Google Scholar
8. 1. Bloem BR
   2. Okun MS
   3. Klein C

   (2021) Parkinson’s disease

   The Lancet 397:2284–2303.

   https://doi.org/10.1016/S0140-6736(21)00218-X

   • Google Scholar
9. 1. Burn DJ
   2. Rowan EN
   3. Allan LM
   4. Molloy S
   5. O’Brien JT
   6. McKeith IG

   (2006) Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies

   Journal of Neurology, Neurosurgery, and Psychiatry 77:585–589.

   https://doi.org/10.1136/jnnp.2005.081711

   • PubMed
   • Google Scholar
10. 1. Chen-Plotkin AS
    2. Albin R
    3. Alcalay R
    4. Babcock D
    5. Bajaj V
    6. Bowman D
    7. Buko A
    8. Cedarbaum J
    9. Chelsky D
    10. Cookson MR
    11. Dawson TM
    12. Dewey R
    13. Foroud T
    14. Frasier M
    15. German D
    16. Gwinn K
    17. Huang X
    18. Kopil C
    19. Kremer T
    20. Lasch S
    21. Marek K
    22. Marto JA
    23. Merchant K
    24. Mollenhauer B
    25. Naito A
    26. Potashkin J
    27. Reimer A
    28. Rosenthal LS
    29. Saunders-Pullman R
    30. Scherzer CR
    31. Sherer T
    32. Singleton A
    33. Sutherland M
    34. Thiele I
    35. van der Brug M
    36. Van Keuren-Jensen K
    37. Vaillancourt D
    38. Walt D
    39. West A
    40. Zhang J

    (2018) Finding useful biomarkers for Parkinson’s disease

    Science Translational Medicine 10:eaam6003.

    https://doi.org/10.1126/scitranslmed.aam6003

    • PubMed
    • Google Scholar
11. 1. Chou SY
    2. Chan L
    3. Chung CC
    4. Chiu JY
    5. Hsieh YC
    6. Hong CT

    (2020) Altered Insulin Receptor Substrate 1 Phosphorylation in Blood Neuron-Derived Extracellular Vesicles From Patients With Parkinson’s Disease

    Frontiers in Cell and Developmental Biology 8:564641.

    https://doi.org/10.3389/fcell.2020.564641

    • PubMed
    • Google Scholar
12. 1. Chou SY
    2. Bamodu OA
    3. Chiu WT
    4. Hong CT
    5. Chan L
    6. Chung CC

    (2022) Artificial neural network-boosted Cardiac Arrest Survival Post-Resuscitation In-hospital (CASPRI) score accurately predicts outcome in cardiac arrest patients treated with targeted temperature management

    Scientific Reports 12:7254.

    https://doi.org/10.1038/s41598-022-11201-z

    • Google Scholar
13. 1. Chung CC
    2. Chan L
    3. Chen JH
    4. Bamodu OA
    5. Hong CT

    (2020a) Neurofilament light chain level in plasma extracellular vesicles and Parkinson’s disease

    Therapeutic Advances in Neurological Disorders 13:1756286420975917.

    https://doi.org/10.1177/1756286420975917

    • PubMed
    • Google Scholar
14. 1. Chung CC
    2. Hong CT
    3. Huang YH
    4. Su ECY
    5. Chan L
    6. Hu CJ
    7. Chiu HW

    (2020b) Predicting major neurologic improvement and long-term outcome after thrombolysis using artificial neural networks

    Journal of the Neurological Sciences 410:116667.

    https://doi.org/10.1016/j.jns.2020.116667

    • PubMed
    • Google Scholar
15. 1. Chung CC
    2. Chan L
    3. Bamodu OA
    4. Hong CT
    5. Chiu HW

    (2020c) Artificial neural network based prediction of postthrombolysis intracerebral hemorrhage and death

    Scientific Reports 10:20501.

    https://doi.org/10.1038/s41598-020-77546-5

    • PubMed
    • Google Scholar
16. 1. Chung CC
    2. Huang PH
    3. Chan L
    4. Chen JH
    5. Chien LN
    6. Hong CT

    (2020d) Plasma Exosomal Brain-Derived Neurotrophic Factor Correlated with the Postural Instability and Gait Disturbance–Related Motor Symptoms in Patients with Parkinson’s Disease

    Diagnostics 10:684.

    https://doi.org/10.3390/diagnostics10090684

    • Google Scholar
17. 1. Chung SJ
    2. Lee JJ
    3. Lee PH
    4. Sohn YH

    (2020e) Emerging Concepts of Motor Reserve in Parkinson’s Disease

    Journal of Movement Disorders 13:171–184.

    https://doi.org/10.14802/jmd.20029

    • Google Scholar
18. 1. Chung CC
    2. Chan L
    3. Chen JH
    4. Bamodu OA
    5. Chiu HW
    6. Hong CT

    (2021a) Plasma extracellular vesicles tau and β-amyloid as biomarkers of cognitive dysfunction of Parkinson’s disease

    FASEB Journal 35:e21895.

    https://doi.org/10.1096/fj.202100787R

    • PubMed
    • Google Scholar
19. 1. Chung CC
    2. Chan L
    3. Chen JH
    4. Hung YC
    5. Hong CT

    (2021b) Plasma extracellular vesicle α-synuclein level in patients with Parkinson’s Disease

    Biomolecules 11:744.

    https://doi.org/10.3390/biom11050744

    • PubMed
    • Google Scholar
20. 1. Courtney NA
    2. Bao H
    3. Briguglio JS
    4. Chapman ER

    (2019) Synaptotagmin 1 clamps synaptic vesicle fusion in mammalian neurons independent of complexin

    Nature Communications 10:4076.

    https://doi.org/10.1038/s41467-019-12015-w

    • PubMed
    • Google Scholar
21. 1. de Lau LML
    2. Breteler MMB

    (2006) Epidemiology of Parkinson’s disease

    The Lancet Neurology 5:525–535.

    https://doi.org/10.1016/S1474-4422(06)70471-9

    • PubMed
    • Google Scholar
22. 1. Duarte PS

    (2021) Cut points identification of continuous biomarkers: A challenge that goes beyond statistical aspects

    Journal of Nuclear Medicine 62:1833.

    https://doi.org/10.2967/jnumed.121.262905

    • PubMed
    • Google Scholar
23. 1. Gcwensa NZ
    2. Russell DL
    3. Cowell RM
    4. Volpicelli-Daley LA

    (2021) Molecular mechanisms underlying synaptic and axon degeneration in Parkinson’s Disease

    Frontiers in Cellular Neuroscience 15:626128.

    https://doi.org/10.3389/fncel.2021.626128

    • PubMed
    • Google Scholar
24. 1. Goetzl EJ
    2. Kapogiannis D
    3. Schwartz JB
    4. Lobach IV
    5. Goetzl L
    6. Abner EL
    7. Jicha GA
    8. Karydas AM
    9. Boxer A
    10. Miller BL

    (2016) Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease

    FASEB Journal 30:4141–4148.

    https://doi.org/10.1096/fj.201600816R

    • PubMed
    • Google Scholar
25. 1. Hughes AJ
    2. Daniel SE
    3. Kilford L
    4. Lees AJ

    (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases

    Journal of Neurology, Neurosurgery, and Psychiatry 55:181–184.

    https://doi.org/10.1136/jnnp.55.3.181

    • PubMed
    • Google Scholar
26. 1. Iseki E
    2. Kato M
    3. Marui W
    4. Uéda K
    5. Kosaka K

    (2001) A neuropathological study of the disturbance of the nigro-amygdaloid connections in brains from patients with dementia with Lewy bodies

    Journal of the Neurological Sciences 185:129–134.

    https://doi.org/10.1016/s0022-510x(01)00481-6

    • PubMed
    • Google Scholar
27. 1. James C
    2. Ranson JM
    3. Everson R
    4. Llewellyn DJ

    (2021) Performance of Machine Learning Algorithms for Predicting Progression to Dementia in Memory Clinic Patients

    JAMA Network Open 4:e2136553.

    https://doi.org/10.1001/jamanetworkopen.2021.36553

    • PubMed
    • Google Scholar
28. 1. Jan AT
    2. Malik MA
    3. Rahman S
    4. Yeo HR
    5. Lee EJ
    6. Abdullah TS
    7. Choi I

    (2017) Perspective Insights of Exosomes in Neurodegenerative Diseases: A Critical Appraisal

    Frontiers in Aging Neuroscience 9:317.

    https://doi.org/10.3389/fnagi.2017.00317

    • PubMed
    • Google Scholar
29. 1. Jia L
    2. Zhu M
    3. Kong C
    4. Pang Y
    5. Zhang H
    6. Qiu Q
    7. Wei C
    8. Tang Y
    9. Wang Q
    10. Li Y
    11. Li T
    12. Li F
    13. Wang Q
    14. Li Y
    15. Wei Y
    16. Jia J

    (2021) Blood neuro-exosomal synaptic proteins predict Alzheimer’s disease at the asymptomatic stage

    Alzheimer’s & Dementia 17:49–60.

    https://doi.org/10.1002/alz.12166

    • PubMed
    • Google Scholar
30. 1. Johnson AR
    2. Bucks RS
    3. Kane RT
    4. Thomas MG
    5. Gasson N
    6. Loftus AM

    (2016) Motor subtype as a predictor of future working memory performance in idiopathic Parkinson’s Disease

    PLOS ONE 11:e0152534.

    https://doi.org/10.1371/journal.pone.0152534

    • PubMed
    • Google Scholar
31. 1. Kalra H
    2. Adda CG
    3. Liem M
    4. Ang CS
    5. Mechler A
    6. Simpson RJ
    7. Hulett MD
    8. Mathivanan S

    (2013) Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma

    Proteomics 13:3354–3364.

    https://doi.org/10.1002/pmic.201300282

    • PubMed
    • Google Scholar
32. 1. Kempster PA
    2. Williams DR
    3. Selikhova M
    4. Holton J
    5. Revesz T
    6. Lees AJ

    (2007) Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study

    Brain 130:2123–2128.

    https://doi.org/10.1093/brain/awm142

    • PubMed
    • Google Scholar
33. 1. Kordower JH
    2. Olanow CW
    3. Dodiya HB
    4. Chu Y
    5. Beach TG
    6. Adler CH
    7. Halliday GM
    8. Bartus RT

    (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease

    Brain 136:2419–2431.

    https://doi.org/10.1093/brain/awt192

    • PubMed
    • Google Scholar
34. 1. Lee JW
    2. Song YS
    3. Kim H
    4. Ku BD
    5. Lee WW

    (2019) Alteration of tremor dominant and postural instability gait difficulty subtypes during the progression of Parkinson’s Disease: Analysis of the PPMI Cohort

    Frontiers in Neurology 10:471.

    https://doi.org/10.3389/fneur.2019.00471

    • PubMed
    • Google Scholar
35. 1. Leggio L
    2. Paternò G
    3. Vivarelli S
    4. Falzone GG
    5. Giachino C
    6. Marchetti B
    7. Iraci N

    (2021) Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson’s Disease

    Aging and Disease 12:1494–1515.

    https://doi.org/10.14336/AD.2021.0527

    • PubMed
    • Google Scholar
36. 1. Lewis SJG
    2. Foltynie T
    3. Blackwell AD
    4. Robbins TW
    5. Owen AM
    6. Barker RA

    (2005) Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach

    Journal of Neurology, Neurosurgery, and Psychiatry 76:343–348.

    https://doi.org/10.1136/jnnp.2003.033530

    • PubMed
    • Google Scholar
37. 1. Lleó A
    2. Núñez-Llaves R
    3. Alcolea D
    4. Chiva C
    5. Balateu-Paños D
    6. Colom-Cadena M
    7. Gomez-Giro G
    8. Muñoz L
    9. Querol-Vilaseca M
    10. Pegueroles J
    11. Rami L
    12. Lladó A
    13. Molinuevo JL
    14. Tainta M
    15. Clarimón J
    16. Spires-Jones T
    17. Blesa R
    18. Fortea J
    19. Martínez-Lage P
    20. Sánchez-Valle R
    21. Sabidó E
    22. Bayés À
    23. Belbin O

    (2019) Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer’s Disease Cerebrospinal Fluid

    Molecular & Cellular Proteomics 18:546–560.

    https://doi.org/10.1074/mcp.RA118.001290

    • PubMed
    • Google Scholar
38. 1. Milà-Alomà M
    2. Brinkmalm A
    3. Ashton NJ
    4. Kvartsberg H
    5. Shekari M
    6. Operto G
    7. Salvadó G
    8. Falcon C
    9. Gispert JD
    10. Vilor-Tejedor N
    11. Arenaza-Urquijo EM
    12. Grau-Rivera O
    13. Sala-Vila A
    14. Sanchez-Benavides G
    15. González-de-Echávarri JM
    16. Minguillon C
    17. Fauria K
    18. Niñerola-Baizán A
    19. Perissinotti A
    20. Kollmorgen G
    21. Suridjan I
    22. Zetterberg H
    23. Molinuevo JL
    24. Blennow K
    25. Suárez-Calvet M
    26. Beteta A
    27. Cacciaglia R
    28. Cañas A
    29. Deulofeu C
    30. Cumplido I
    31. Dominguez R
    32. Emilio M
    33. Fuentes S
    34. Hernandez L
    35. Huesa G
    36. Huguet J
    37. Marne P
    38. Mench´on T
    39. Polo A
    40. Pradas S
    41. Soteras A
    42. Vilanova M
    43. on behalf of the ALFA Study

    (2021) CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET: A Cross-sectional Study

    Neurology 97:e2065–e2078.

    https://doi.org/10.1212/WNL.0000000000012853

    • PubMed
    • Google Scholar
39. 1. Niu M
    2. Li Y
    3. Li G
    4. Zhou L
    5. Luo N
    6. Yao M
    7. Kang W
    8. Liu J

    (2020) A longitudinal study on α-synuclein in plasma neuronal exosomes as A biomarker for Parkinson’s disease development and progression

    European Journal of Neurology 27:967–974.

    https://doi.org/10.1111/ene.14208

    • PubMed
    • Google Scholar
40. 1. Nutt JG

    (2016) Motor subtype in Parkinson’s disease: Different disorders or different stages of disease?

    Movement Disorders 31:957–961.

    https://doi.org/10.1002/mds.26657

    • PubMed
    • Google Scholar
41. 1. Öhrfelt A
    2. Brinkmalm A
    3. Dumurgier J
    4. Zetterberg H
    5. Bouaziz-Amar E
    6. Hugon J
    7. Paquet C
    8. Blennow K

    (2019) A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer’s Disease

    Neuroscience 420:136–144.

    https://doi.org/10.1016/j.neuroscience.2018.11.038

    • PubMed
    • Google Scholar
42. 1. Picconi B
    2. Piccoli G
    3. Calabresi P

    (2012) Synaptic dysfunction in Parkinson’s disease

    Advances in Experimental Medicine and Biology 970:553–572.

    https://doi.org/10.1007/978-3-7091-0932-8_24

    • PubMed
    • Google Scholar
43. 1. Qin XY
    2. Zhang SP
    3. Cao C
    4. Loh YP
    5. Cheng Y

    (2016) Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis

    JAMA Neurology 73:1316–1324.

    https://doi.org/10.1001/jamaneurol.2016.2742

    • PubMed
    • Google Scholar
44. 1. Ren J
    2. Hua P
    3. Li Y
    4. Pan C
    5. Yan L
    6. Yu C
    7. Zhang L
    8. Xu P
    9. Zhang M
    10. Liu W

    (2020) Comparison of Three Motor Subtype Classifications in de novo Parkinson’s Disease Patients

    Frontiers in Neurology 11:601225.

    https://doi.org/10.3389/fneur.2020.601225

    • PubMed
    • Google Scholar
45. 1. Rodriguez-Blazquez C
    2. Rojo-Abuin JM
    3. Alvarez-Sanchez M
    4. Arakaki T
    5. Bergareche-Yarza A
    6. Chade A
    7. Garretto N
    8. Gershanik O
    9. Kurtis MM
    10. Martinez-Castrillo JC
    11. Mendoza-Rodriguez A
    12. Moore HP
    13. Rodriguez-Violante M
    14. Singer C
    15. Tilley BC
    16. Huang J
    17. Stebbins GT
    18. Goetz CG
    19. Martinez-Martin P

    (2013) The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson’s disease

    Parkinsonism & Related Disorders 19:889–893.

    https://doi.org/10.1016/j.parkreldis.2013.05.017

    • PubMed
    • Google Scholar
46. 1. Sampaio C

    (2009) Can focusing on UPDRS Part II make assessments of Parkinson disease progression more efficient?

    Nature Clinical Practice. Neurology 5:130–131.

    https://doi.org/10.1038/ncpneuro1049

    • PubMed
    • Google Scholar
47. 1. Si X
    2. Tian J
    3. Chen Y
    4. Yan Y
    5. Pu J
    6. Zhang B

    (2019) Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson’s Disease

    Neuroscience 413:308–316.

    https://doi.org/10.1016/j.neuroscience.2019.05.015

    • PubMed
    • Google Scholar
48. 1. Sjögren M
    2. Davidsson P
    3. Gottfries J
    4. Vanderstichele H
    5. Edman A
    6. Vanmechelen E
    7. Wallin A
    8. Blennow K

    (2001) The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer’s disease, reflecting a common pathophysiological process

    Dementia and Geriatric Cognitive Disorders 12:257–264.

    https://doi.org/10.1159/000051268

    • PubMed
    • Google Scholar
49. 1. Stephens B
    2. Mueller AJ
    3. Shering AF
    4. Hood SH
    5. Taggart P
    6. Arbuthnott GW
    7. Bell JE
    8. Kilford L
    9. Kingsbury AE
    10. Daniel SE
    11. Ingham CA

    (2005) Evidence of a breakdown of corticostriatal connections in Parkinson’s disease

    Neuroscience 132:741–754.

    https://doi.org/10.1016/j.neuroscience.2005.01.007

    • PubMed
    • Google Scholar
50. 1. Stuendl A
    2. Kraus T
    3. Chatterjee M
    4. Zapke B
    5. Sadowski B
    6. Moebius W
    7. Hobert MA
    8. Deuschle C
    9. Brockmann K
    10. Maetzler W
    11. Mollenhauer B
    12. Schneider A

    (2021) α-Synuclein in plasma-derived extracellular vesicles is a potential biomarker of Parkinson’s Disease

    Movement Disorders 36:2508–2518.

    https://doi.org/10.1002/mds.28639

    • PubMed
    • Google Scholar
51. 1. Sunwoo MK
    2. Lee JE
    3. Hong JY
    4. Ye BS
    5. Lee HS
    6. Oh JS
    7. Kim JS
    8. Lee PH
    9. Sohn YH

    (2017) Premorbid exercise engagement and motor reserve in Parkinson’s disease

    Parkinsonism & Related Disorders 34:49–53.

    https://doi.org/10.1016/j.parkreldis.2016.10.023

    • PubMed
    • Google Scholar
52. 1. Zheng H
    2. Xie Z
    3. Zhang X
    4. Mao J
    5. Wang M
    6. Wei S
    7. Fu Y
    8. Zheng H
    9. He Y
    10. Chen H
    11. Xu Y

    (2021) Investigation of α-synuclein species in plasma exosomes and the oligomeric and phosphorylated α-synuclein as potential peripheral biomarker of parkinson’s disease

    Neuroscience 469:79–90.

    https://doi.org/10.1016/j.neuroscience.2021.06.033

    • PubMed
    • Google Scholar

Author details

1. Chien-Tai Hong

   1. Department of Neurology, Shuang Ho Hospital, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan
   2. Department of Neurology, School of Medicine, College of Medicine Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan
   3. Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan

   Contribution

   Conceptualization, Resources, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-7448-1041

2. Chen-Chih Chung

   1. Department of Neurology, Shuang Ho Hospital, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan
   2. Department of Neurology, School of Medicine, College of Medicine Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan
   3. Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan

   Contribution

   Resources, Data curation, Software, Funding acquisition, Investigation, Methodology, Writing – review and editing

   Competing interests

   No competing interests declared

3. Ruan-Ching Yu

   Division of Psychiatry, University College London, London, United Kingdom

   Contribution

   Data curation, Formal analysis, Methodology

   Competing interests

   No competing interests declared

4. Lung Chan

   1. Department of Neurology, Shuang Ho Hospital, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan
   2. Department of Neurology, School of Medicine, College of Medicine Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan
   3. Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan

   Contribution

   Conceptualization, Resources, Data curation, Software, Validation, Investigation, Writing – review and editing

   For correspondence

   cjustinmd@tmu.edu.tw

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-5795-4460

• 909

  views

• 69

  downloads

• 0

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.